Merck Announces Third-Quarter 2017 Dividend
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Board of Directors has declared a quarterly
dividend of $0.47 per share of the company ’s common stock for the third
quarter of 2017. Payment will be made on July 10, 2017 to shareholders
of record at the close of business on June 15, 2017.About MerckLanguage:
EnglishContact: Media:Tracy Ogden, 908-740-1747Claire Gillespie, 267-305-0932Investor:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSE
@Merck...
Source: Merck.com - Corporate News - May 23, 2017 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news
Data for KEYTRUDA ® (pembrolizumab) Across 16 Types of Cancer from Merck’s Industry-Leading Immuno-Oncology Program to Be Presented at the 2017 ASCO Annual Meeting
Dateline City:
KENILWORTH, N.J. Research with KEYTRUDA in Monotherapy and in Combination Includes Findings in Non-Small Cell Lung Cancer (NSCLC), Melanoma, Urothelial Carcinoma, Microsatellite-Instability High (MSI-H) Cancers, Gastric Cancer and Breast Cancer New Overall Survival Data to be Presented in NSCLC, Melanoma and Urothelial CarcinomaKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that new and updated data from studies of KEYTRUDA®
(pembrolizumab), the company ’s anti-PD-1 therapy, will be presented at
the 53rd An...
Source: Merck.com - Corporate News - May 17, 2017 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK NYSE: MRK Source Type: news
Merck to Present at the Deutsche Bank 42nd Annual Health Care Conference
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that Roger Perlmutter, president, Merck Research
Laboratories, is scheduled to present at the Deutsche Bank 42nd Annual
Health Care Conference in Boston on May 4, 2017 at 8:40 a.m. EDT.
Investors, analysts, members of the media and the general public are
invited to listen to a live audio webcast of the presentation at http://investors.merck.com/events-and-presentations/default.aspx.About MerckLanguage:
EnglishContact: Media:Claire Gillespie, 26...
Source: Merck.com - Corporate News - May 3, 2017 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news
Merck Announces First-Quarter 2017 Financial Results
Dateline City:
KENILWORTH, N.J. First-Quarter 2017 Worldwide Sales Were $9.4 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange First-Quarter 2017 GAAP EPS Was $0.56; First-Quarter Non-GAAP EPS Was $0.88 Company Narrows and Raises 2017 Full-Year Revenue Range to be Between $39.1 Billion and $40.3 Billion, Including an Approximately 1.5 Percent Negative Impact from Foreign Exchange Company Narrows and Raises 2017 Full-Year GAAP EPS Range to be Between $2.51 and $2.63; Narrows and Raises 2017 Full-Year Non-GAAP EPS Range to be Between $3.76 and $3.88, Inclu...
Source: Merck.com - Corporate News - May 2, 2017 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK earnings MSD NYSE:MRK Source Type: news
America ’s Diabetes Challenge Unveils Common Challenges Affecting the Type 2 Diabetes Community
Dateline City:
KENILWORTH, N.J.Merck, the American Diabetes Association and Celebrity Voices Offer Tips to Help People Tackle Their Obstacles Head OnKENILWORTH, N.J. – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the American Diabetes Association today revealed common challenges affecting the millions of Americans living with type 2 diabetes as part of the programAmerica ’s Diabetes Challenge: Get to Your Goals. Last year, award-winning artist Tim McGraw, renowned actress S. Epatha Merkerson and Chef Leticia Moreinos Schwartz called on patients and their loved ones to share the...
Source: Merck.com - Corporate News - April 25, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Donates $300,000 to Support Neglected Tropical Disease Elimination Efforts in Africa
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, announced
today a $300,000 cash donation to support non-governmental organization
(NGO) partners working to eliminate river blindness (onchocerciasis) and
lymphatic filariasis (LF) in Africa.Language:
EnglishContact: Merck:Claire Gillespie, 267-305-0932Jeanine Clemente, 908-740-6268orMDP:Joni Lawrence, 404-687-5610Yao Sodahlon, 404-371-1460Ticker Slug:Ticker:MRKExchange:NYSE
@Merckread more (Source: Merck.com - Corporate News)
Source: Merck.com - Corporate News - April 20, 2017 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news
Togo Becomes First Country in Africa to Validate the Elimination of Lymphatic Filariasis as a Public Health Problem
Dateline City:
LOME, TOGOLOME, TOGO -- GSK, Merck (known as MSD outside the United States and Canada), and the MECTIZAN® Donation Program (MDP) congratulate President Faure Gnassingb é, the government and the people of Togo for becoming the first country in Africa recognized by the World Health Organization to have eliminated lymphatic filariasis (LF) as a public health problem.Language:
Englishread more (Source: Merck.com - Corporate News)
Source: Merck.com - Corporate News - April 18, 2017 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News Source Type: news
Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that Dr. John H. Noseworthy, president and chief
executive officer of Mayo Clinic, has been nominated to stand for
election to the company ’s board of directors. The annual election of Dr.
Noseworthy and the other directors will take place in connection with
Merck’s Annual Meeting of Shareholders on May 23, 2017. With the
proposed addition of Dr. Noseworthy, and the planned retirement of C.Language:
EnglishContact: MerckMedia:Tracy O...
Source: Merck.com - Corporate News - April 10, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news
Merck Receives Complete Response Letter from the U.S. FDA for TECOS Study with Sitagliptin
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
issued a Complete Response Letter regarding Merck ’s Supplemental New
Drug Applications for JANUVIA®(sitagliptin), JANUMET®
(sitagliptin and metformin HCl) and JANUMET XR® (sitagliptin
and metformin HCl extended-release).Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orKristen Drake, 908-236-4223orInvestors:Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NY...
Source: Merck.com - Corporate News - April 7, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news
Merck Receives 2017 ENERGY STAR Sustained Excellence Award from U. S. Environmental Protection Agency
Dateline City:
KENILWORTH, N.J. Company Receives EPA Honor for 12th Consecutive YearKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that it has received an ENERGY STAR 2017 Partner of the
Year – Sustained Excellence Award from the U.S. Environmental Protection
Agency (EPA) for its continued improvement of energy performance and
leadership in energy management in both the pharmaceutical and
industrial sectors.Language:
EnglishContact: MerckMedia:Claire Gillespie, 267-305-0932orInvestors:Amy Klug, 908-740-1898Ticker Slug...
Source: Merck.com - Corporate News - April 6, 2017 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News #Merck #MRK $MRK Energy Star MSD NYSE:MRK Source Type: news
Merck to Hold First-Quarter 2017 Sales and Earnings Conference Call on May 2
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
will hold its first-quarter 2017 sales and earnings conference call with
institutional investors and analysts at 8:00 a.m. EDT on Tuesday, May 2.
During the call, company executives will provide an overview of Merck ’s
performance for the quarter and year.Language:
EnglishContact: MerckMedia:Claire Gillespie, 267-305-0932orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSE
@Merckread more (Source: Merck.com - Corporate News)
Source: Merck.com - Corporate News - April 3, 2017 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK earnings MSD NYSE:MRK Source Type: news
Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA ® (pembrolizumab)
Dateline City:
WILMINGTON, Del.& KENILWORTH, N.J.Clinical Program Now Includes Seven Registrational Trials Across Five Tumor TypesWILMINGTON, Del.& KENILWORTH, N.J.–Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional details of their clinical development program investigating the combination of epacadostat, Incyte ’s investigational oral selective IDO1 enzyme inhibitor, with KEYTRUDA® (pembrolizumab), Merck ’s anti-PD-1 therapy, in patients across five tumor types: metastatic melanoma, non-small cell lung can...
Source: Merck.com - Corporate News - March 31, 2017 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news
Merck Animal Health Completes Acquisition of Vall ée S.A.
Dateline City:
MADISON, N.J. Broadening Our Comprehensive Portfolio of Animal Health Products for Brazilian MarketMADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health (known as MSD Animal Health outside the United
States and Canada) today announced it has successfully acquired a
controlling interest in Vall ée S.A., a leading privately-held producer
of animal health products in Brazil.Language:
EnglishContact: For MerckMedia:Noreen Verbrugge, 973-937-5450orPamela Eisele, 267-305-3558orInvestors:Michael DeCarbo, 908-740-1807Ticker Slug:Ticker:MRKExchange:NYSE
@MerckAHread more (Source: Mer...
Source: Merck.com - Corporate News - March 22, 2017 Category: Pharmaceuticals Tags: Corporate News Animal Health Latest News #Merck #MRK $MRK Merck Animal Health MSD NYSE:MRK Vall ée S.A. Source Type: news
FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
Dateline City:
KENILWORTH, N.J. Only Anti-PD-1 Therapy Approved for the Treatment of Patients with Difficult-to-Treat cHL Regardless of Prior Stem Cell Transplantation or Use of Brentuximab VedotinKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved KEYTRUDA®(pembrolizumab), the company ’s anti-PD-1
(programmed death receptor-1) therapy, for the treatment of adult and
pediatric patients with refractory classical Hodgkin lymphoma (cHL), or
who have relapsed after t...
Source: Merck.com - Corporate News - March 14, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK NYSE:MRK Source Type: news
Merck Provides Update on Supplemental Biologics License Application (sBLA) for KEYTRUDA ® (pembrolizumab) in Previously Treated Advanced Microsatellite Instability-High Cancer
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
extended the action date for the supplemental Biologics License
Application (sBLA) for KEYTRUDA®(pembrolizumab), the
company ’s anti-PD-1 therapy, for previously treated patients with
advanced microsatellite instability-high (MSI-H) cancer. The company
recently submitted additional data and analyses to the FDA related to
the pending application.Language:
EnglishContact: MerckMedia:...
Source: Merck.com - Corporate News - March 14, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK NYSE: MRK Source Type: news
Merck Announces Second-Quarter 2017 Dividend
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the Board of Directors has declared a quarterly
dividend of $0.47 per share of the company ’s common stock for the second
quarter of 2017. Payment will be made on April 7, 2017 to shareholders
of record at the close of business on March 15, 2017.About MerckLanguage:
EnglishContact: MerckMedia:Lainie Keller, 908-236-5036orClaire Gillespie, 267-305-0932orInvestor:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange...
Source: Merck.com - Corporate News - February 28, 2017 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news
Recent Survey Finds Many Adults with Diabetes Unaware of Their Increased Risk for Certain Serious Illnesses
Discussions Between Health Care Professionals and Patients to Help Them Understand Their Increased Risk For Pneumococcal Pneumonia/Pneumococcal Disease, Flu and Hepatitis BKENILWORTH, N.J.--(BUSINESS WIRE)--Many adults with diabetes are unaware of their increased risk for
certain serious illnesses, including pneumococcal pneumonia/pneumococcal
disease, flu and hepatitis B. This is according to a recent national,
online consumer awareness survey sponsored by Merck (NYSE:MRK), known as
MSD outside the United States and Canada, and the American Diabetes
Association, and conducted by Harris Poll.Language:
...
Source: Merck.com - Corporate News - February 28, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK Diabetes MSD NYSE:MRK Source Type: news
Merck ’s Fight Against Infectious Disease Goes Digital with Launch of ILÚM Health Solutions
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the launch of IL ÚM Health Solutions, which provides
enterprise-wide disease management tools and services to enable improved
outcomes for patients with infectious diseases, such as sepsis and
pneumonia, while supporting antimicrobial stewardship initiatives. ILÚM
operates independently from Merck’s pharmaceutical and vaccine products
businesses as part of Merck’s Healthcare Services& Solutions (HSS)
group.Language:
...
Source: Merck.com - Corporate News - February 16, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK ILUM MSD NYSE:MRK Source Type: news
Merck Foundation Announces Six Program Grant Recipients for Alliance to Advance Patient-Centered Cancer Care
Dateline City:
KENILWORTH, N.J. Alliance Aims to Reduce Disparities in Access to High-Quality Cancer CareKENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation (Foundation), announced today the selection of the
six program sites and National Program Office forming theAlliance
to Advance Patient-Centered Cancer Care (theAlliance).
With $15 million in funding from the Foundation over five years, theAlliance
aims to increase timely access to patient-centered cancer care for
vulnerable and underserved populations in the United States.Language:
EnglishContact: For Merck:Media:Lainie Keller, 908-236-...
Source: Merck.com - Corporate News - February 9, 2017 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News #Merck #MRK $MRK Merck Foundation MSD NYSE:MRK Source Type: news
FDA Accepts Two sBLAs for Merck ’s KEYTRUDA® (pembrolizumab) for Locally Advanced or Metastatic Urothelial Cancer in Cisplatin-Ineligible First-Line and Second-Line Post-Platinum Failure Treatment Settings
Dateline City:
KENILWORTH, N.J. KEYTRUDA Also Receives Breakthrough Therapy Designation for Second-Line Treatment Based on KEYNOTE-045, Which Includes Primary Endpoints of Overall Survival and Progression-Free SurvivalKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
accepted for review two supplemental Biologics License Applications
(sBLAs) for KEYTRUDA® (pembrolizumab), the company ’s
anti-PD-1 therapy, in patients with locally advanced or metastatic
urothelial cancer...
Source: Merck.com - Corporate News - February 3, 2017 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD NYSE:MRK Source Type: news
Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results
Dateline City:
KENILWORTH, N.J. Fourth-Quarter 2016 Worldwide Sales Were $10.1 Billion, a Decrease of 1 Percent, Including a 1 Percent Negative Impact from Foreign Exchange; Full-Year 2016 Worldwide Sales Were $39.8 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange Fourth-Quarter 2016 GAAP EPS Was $0.42; Fourth-Quarter Non-GAAP EPS Was $0.89; Full-Year 2016 GAAP EPS Was $2.04; Full-Year Non-GAAP EPS Was $3.78 2017 Financial Outlook Expects Full-Year 2017 GAAP EPS to be Between $2.47 and $2.62; Expects Non-GAAP EPS to be Between $3.72 and $3.87, Inclu...
Source: Merck.com - Corporate News - February 2, 2017 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK earnings MSD NYSE:MRK Source Type: news
European Commission Approves KEYTRUDA ® (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations
Dateline City:
KENILWORTH, N.J. Approval Based on Data Showing Improved Overall Survival and Progression-Free Survival with KEYTRUDA Compared to Chemotherapy First Anti-PD-1 Therapy Approved in Europe for Previously Untreated Patients with Metastatic NSCLCKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the European Commission has approved KEYTRUDA®
(pembrolizumab), the company ’s anti-PD-1 therapy, for the first-line
treatment of metastatic non-small cell lung cancer (NSCLC) in adults
whose tumors have high PD-L1 exp...
Source: Merck.com - Corporate News - January 31, 2017 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK Keytruda MSD NSCLC NYSE:MRK Source Type: news
Pro Football Hall of Famer and Cancer Survivor Jim Kelly Teams Up with Merck and Leading Cancer Organizations to Launch Your Cancer Game Plan
Dateline City:
KENILWORTH, N.J. Kelly Provides His “Game Plan” for Navigating Head and Neck CancerKENILWORTH, N.J.--(BUSINESS WIRE)--Head and neck cancer survivor and Pro Football Hall of Famer Jim Kelly
is sharing his personal experience as part ofYour Cancer Game Plan,
a new awareness campaign focused on helping people with cancer and their
loved ones tackle their emotional, nutritional and communication needs.
Kelly, one of the toughest quarterbacks to have played Pro Football,
successfully handled the gridiron with his motto ‘Kelly Tough’ – a motto
that took on new ...
Source: Merck.com - Corporate News - January 25, 2017 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK cancer Jim Kelly MSD NYSE:MRK Source Type: news
Merck Announces Settlement and License Agreement Resolving KEYTRUDA ® (pembrolizumab) Patent Litigation
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada),
and certain of its affiliates, today announced it agreed to enter into a
settlement and license agreement with Bristol-Myers Squibb Company and
Ono Pharmaceutical Co., Ltd., resolving the worldwide patent
infringement litigation related to the use of an anti-PD-1 antibody for
the treatment of cancer, such as KEYTRUDA® (pembrolizumab).Language:
EnglishContact: Merck Media:Pamela Eisele, 267-305-3558Claire Gillespie, 267-305-0932or Investors:Teri Loxam, 908-74...
Source: Merck.com - Corporate News - January 20, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news
MSD for Mothers Commits $10 Million and Business Expertise to the Global Financing Facility to Help End Preventable Deaths of Mothers
Dateline City:
DAVOS, Switzerland Represents a Critical Step toward Meeting the Sustainable Development Goals for Women, Children and Adolescent HealthDAVOS, Switzerland--(BUSINESS WIRE)--MSD, known as Merck& Co., Inc., Kenilworth, N.J., U.S.A., inside the
United States and Canada, announced today its $10 million commitment to
the Global Financing Facility (GFF) in support ofEvery Woman Every
Child to improve maternal and child health in low- and
lower-middle-income countries worldwide through itsMSD for Mothers
initiative.Language:
EnglishContact: Media: MSD for MothersLainie Keller, 908-23...
Source: Merck.com - Corporate News - January 19, 2017 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News #Merck #MRK $MRK GFF Global Financing Facility MSD MSD for Mothers NYSE:MRK World Bank Source Type: news
Merck Foundation Grant Expands Project ECHO ® in Vietnam and India
Dateline City:
KENILWORTH, N.J. Project Increases Access to Specialty Care for Complex, Chronic ConditionsKENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation (Foundation) and the Extension for Community
Healthcare Outcomes (ECHO) Institute ™ at the University of New Mexico
Health Sciences Center announced today that the Foundation has provided
a grant of $7 million over five years to support the expansion ofProject
ECHO® to improve access to specialty care for complex,
chronic conditions, such as: hepatitis C, HIV, tuberculosis, and
non-communicable diseases, including diabetes and me...
Source: Merck.com - Corporate News - January 18, 2017 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News #Merck #MRK $MRK Merck Foundation MSD NYSE:MRK Source Type: news
Merck to Participate at the 35th Annual J.P. Morgan Healthcare Conference
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that Kenneth C. Frazier, chairman and chief executive
officer, and Dr. Roger M. Perlmutter, president, Merck Research
Laboratories, are scheduled to participate at the 35th Annual
J.P. Morgan Healthcare Conference in San Francisco on Jan. 9, 2017 at
4:00 p.m. PST (7:00 p.m. EST).Language:
EnglishContact: Media:Lainie Keller, 908-236-5036orClaire Gillespie, 267-305-0932orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Tic...
Source: Merck.com - Corporate News - January 6, 2017 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK JP Morgan MSD NYSE:MRK Source Type: news
Merck to Hold Fourth-Quarter and Full-Year 2016 Sales and Earnings Conference Call on February 2
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
will hold its fourth-quarter and full-year 2016 sales and earnings
conference call with institutional investors and analysts at 8:00 a.m.
EST on Thursday, Feb. 2. During the call, company executives will
provide an overview of Merck ’s performance for the quarter and year.Language:
EnglishContact: MerckMedia:Lainie Keller, (908) 236-5036Claire Gillespie, (267) 305-0932orInvestor:Teri Loxam, (908) 740-1986Amy Klug, (908) 740-1898Ticker Slug:Ticker:MRKExchange:...
Source: Merck.com - Corporate News - January 3, 2017 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK earnings MSD NYSE:MRK Source Type: news
European Medicines Agency ’s CHMP Recommends Merck’s KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor...
Dateline City:
KENILWORTH, N.J. Opinion Based on Findings from KEYNOTE-024 Trial, Which Showed Superior Overall Survival and Progression Free Survival with KEYTRUDA Compared to Chemotherapy First Anti-PD-1 Therapy to Receive a CHMP Positive Opinion for Previously Untreated Patients with Metastatic NSCLCKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines Agency (EMA) has adopted a positive
opinion recommending approval of KEYTRUDA ® (pembrolizumab...
Source: Merck.com - Corporate News - December 16, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK CHMP Keytruda MSD NSCLC NYSE:MRK Source Type: news
Interim Results from Phase 1b/2 Study Evaluating the Combination of Merck ’s KEYTRUDA® (pembrolizumab) and Eisai’s HALAVEN® (eribulin mesylate) Injection in Metastatic Triple-Negative Breast Cancer Presented at 2016 SABCS
Dateline City:
KENILWORTH, N.J.& WOODCLIFF LAKE, N.J.KENILWORTH, N.J.& WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Eisai Inc. today announced new interim data investigating Merck ’s
anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in combination
with Eisai ’s microtubule dynamics inhibitor, HALAVEN®
(eribulin), in patients with metastatic triple-negative breast cancer
(TNBC).Language:
EnglishContact: Media:MerckPamela Eisele, 267-305-3558orKim Hamilton, (908) 740-1863orEisai Inc.Laurie Landau, 201-746-25...
Source: Merck.com - Corporate News - December 12, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Eisai HALAVEN Keytruda MSD NYSE:MRK Source Type: news
Merck to Participate at the Citi 2016 Global Healthcare Conference
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that Dr. Roger M. Perlmutter, president, Merck Research
Laboratories, is scheduled to participate at the Citi 2016 Global
Healthcare Conference in New York on Dec. 7, 2016 at 12:35 p.m. EST.
Investors, analysts, members of the media and the general public are
invited to listen to a live audio webcast of the presentation at http://investors.merck.com/investors/webcasts-and-presentations/default.aspx.Language:
EnglishContact: MerckMedia:Lainie K...
Source: Merck.com - Corporate News - December 6, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK Citi MSD NYSE:MRK Source Type: news
FDA Grants Priority Review to Supplemental Biologics License Application (sBLA) for Merck ’s KEYTRUDA® (pembrolizumab) in Relapsed or Refractory Classical Hodgkin Lymphoma
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
accepted for review the supplemental Biologics License Application
(sBLA) for KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1
therapy, for the treatment of patients with refractory classical Hodgkin
lymphoma (cHL) or for patients who have relapsed after three or more
prior lines of therapy.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-186...
Source: Merck.com - Corporate News - December 1, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda MSD Source Type: news
Actress Bellamy Young, Merck, and Leading Lung Cancer Advocates Urge Those Impacted by Lung Cancer to Test. Talk. Take Action.
Dateline City:
KENILWORTH, N.J. Young to Help Educate on the Importance of Biomarker Testing in Non-Small Cell Lung CancerKENILWORTH, N.J.--(BUSINESS WIRE)--Acclaimed actress and singerBellamy Young lost her father to
lung cancer, and she is now sharing her personal experience as part ofTest.
Talk. Take Action., a new awareness campaign focused on increasing
people ’s understanding of biomarkers and the role they play in the
treatment of non-small cell lung cancer (NSCLC).Language:
EnglishContact: MediaMerckCourtney Ronaldo, 908-236-1108orChristiana Pascale, 212-257-6722Media Capsule:iframes...
Source: Merck.com - Corporate News - November 29, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK Lung Cancer MSD Source Type: news
FDA Grants Priority Review to Merck ’s Supplemental Biologics License Application (sBLA) Seeking Approval for KEYTRUDA® (pembrolizumab) for New Indication in Microsatellite Instability-High Cancer
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA)
accepted for review the supplemental Biologics License Application
(sBLA) for KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1
therapy, for the treatment of previously treated patients with advanced
microsatellite instability-high (MSI-H) cancer.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908...
Source: Merck.com - Corporate News - November 28, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda MSD Source Type: news
Merck Announces Increased Quarterly Dividend
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the Board of Directors has increased the company ’s
quarterly dividend to $0.47 per outstanding share of the company’s
common stock, up $0.01 from $0.46 per outstanding share paid last
quarter. Payment will be made on Jan. 9, 2017, to stockholders of record
at the close of business on Dec. 15, 2016.Language:
EnglishContact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898Ticker Slug:...
Source: Merck.com - Corporate News - November 22, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News #MRK $MRK Merck MSD Source Type: news
Merck Foundation Announces $10 Million Initiative to Improve Access to High-Quality Diabetes Care in Vulnerable and Underserved U.S. Communities
Dateline City:
KENILWORTH, N.J. Non-Profit Organizations Invited to Apply for Grants to Improve Access to Diabetes CareKENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation (Foundation) announced today the launch of a new
initiative,Bridging the Gap: Reducing Disparities in Diabetes Care
(Bridging the Gap),to improve access to high-quality diabetes care
and reduce health disparities for vulnerable and underserved populations
in the United States. With $10 million in funding from the Foundation
over five years,Bridging the Gap will build sustainable
partnerships across sectors to support innovativ...
Source: Merck.com - Corporate News - November 17, 2016 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News #Merck #MRK $MRK Diabetes Merck Foundation MSD Source Type: news
Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
Dateline City:
KENILWORTH, N.J. Phase 2 Data Presentations at The Liver Meeting® Detail SVR12 Rates from Two Studies as Well as SVR8 Rates in Patients for Whom Direct-Acting Antiviral Treatment Previously FailedKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced the presentation of results from three Phase 2 clinical
trials evaluating MK-3682B (MK-3682/grazoprevir/ruzasvir1),
the company ’s investigational all-oral, triple-combination regimen for
the treatment of chronic hepatitis C (HCV) infection (informally
referred ...
Source: Merck.com - Corporate News - November 13, 2016 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News #Merck #MRK $MRK MSD Source Type: news
Merck Announces Presentation of New Findings for ZEPATIER ™ (Elbasvir and Grazoprevir) in Patients with Chronic Hepatitis C at The Liver Meeting®
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced results from multiple analyses atThe
Liver Meeting® 2016, which provide additional evidence
supporting the use of ZEPATIER ™ (elbasvir and grazoprevir) 50mg/100mg
tablets in chronic hepatitis C virus (HCV) genotype (GT) 1- or
GT4-infected patient populations, including those who receive opioid
agonist therapy (OAT), are infected with chronic HCV GT1b, use proton
pump inhibitors (PPIs) or ha ve moderate kidney disease. (Source: Merck.com - Corporate News)
Source: Merck.com - Corporate News - November 12, 2016 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News #Merck #MRK $MRK MSD The Liver Meeting ZEPATIER Source Type: news
Merck Prices EUR 1.0 Billion Debt Offering
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck& Co., Inc., (NYSE:MRK), known as MSD outside the United States
and Canada, priced today a EUR 1.0 billion public offering of two series
of Euro-denominated senior unsecured notes (collectively, the “New
Notes”). Based on Oct. 21, 2016, closing exchange rates the EUR 1.0
billion equates to approximately $1.087 billion. The notes include:
EUR 500 million of 0.500% notes due Nov. 2024EUR 500 million of
1.375% notes due Nov. 2036Language:
EnglishContact: Merck& Co., Inc.Media:Lainie Keller, 908-236-5036Tracy ...
Source: Merck.com - Corporate News - October 26, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news
Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More than 30 Data Presentations at ID Week 2016
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that researchers will provide more than 30 scientific
data presentations on the company ’s established and investigational
infectious disease medicines and vaccines at ID Week 2016 in New Orleans
from Oct. 26-30.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558Robert Consalvo, 908-295-0928Skip Irvine, 215-652-6059orInvestors:Amy Klug, 908-740-1898Michael DeCarbo, 908-740-1807Ticker Slug:Ticker:MRKExchange:NYSEread more (Source: ...
Source: Merck.com - Corporate News - October 26, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK Infectious Diseases MSD NYSE:MRK Source Type: news
Merck Announces Third-Quarter 2016 Financial Results
Dateline City:
KENILWORTH, N.J. Third-Quarter 2016 Worldwide Sales Were $10.5 Billion, an Increase of 5 Percent, Including a 1 Percent Negative Impact from Foreign Exchange Third-Quarter 2016 GAAP EPS Was $0.78; Third-Quarter Non-GAAP EPS Was $1.07 Company Updates EPS Guidance: Full-Year 2016 GAAP EPS to be Between $2.02 and $2.09; Full-Year 2016 Non-GAAP EPS to be Between $3.71 and $3.78 Advanced KEYTRUDA Development Program FDA Approved KEYTRUDA for Previously Untreated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score...
Source: Merck.com - Corporate News - October 25, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK earnings MSD NYSE:MRK Source Type: news
FDA Approves Merck ’s ZINPLAVA™ (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection (CDI) in Adult Patients Receiving Antibacterial Drug Treatment for CDI Who Are at High Risk of CDI Recurrence
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved ZINPLAVA ™ (bezlotoxumab) Injection 25 mg/mL. Merck anticipates
making ZINPLAVA available in first quarter 2017.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more (Source: Merck.com - Corporate News)
Source: Merck.com - Corporate News - October 22, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK CDI MSD ZINPLAVA Source Type: news
Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck& Co., Inc. (NYSE: MRK), known as MSD outside the United States
and Canada, today announced that the pivotal Phase 3 clinical study of
letermovir, an investigational antiviral medicine, met its primary
endpoint.Language:
EnglishContact: MerckMedia:Pam Eisele, 267-305-3558Robert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more (Source: Merck.com - Corporate News)
Source: Merck.com - Corporate News - October 19, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK Letermovir MSD NYSE:MRK Source Type: news
Merck Research Laboratories Facilities Designated as “Milestones in Microbiology” Sites by the American Society for Microbiology
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that Merck Research Laboratories (MRL) facilities in
Rahway, N.J., and West Point, Pa., have been designated as “Milestones
in Microbiology” sites by the American Society for Microbiology (ASM)
for their contributions to anti-infectives and vaccines, respectively.
This is the first time a biopharmaceutical company has received this
recognition.Language:
EnglishContact: Media:Pam Eisele, 267-305-3558Ian McConnell, 908-740-1921Investor:...
Source: Merck.com - Corporate News - October 17, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK ASM MSD NYSE:MRK Source Type: news
Merck Launches Biosimilars Clarified, a New Online Educational Resource about Biosimilar Medicines for Patients and the Healthcare Community
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the launch ofBiosimilars Clarified (www.merckclarifiesbiosimilars.com),
a new educational website for patients, caregivers and the healthcare
community that is designed to provide clear, concise and straightforward
information about biosimilar medicines.Language:
EnglishContact: MerckRobert Consalvo, 908-236-1127Ticker Slug:Ticker:MRKExchange:NYSEread more (Source: Merck.com - Corporate News)
Source: Merck.com - Corporate News - October 14, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK biosimilar MSD NYSE:MRK Source Type: news
Merck Animal Health Announces USDA Approval of Innovative Canine Flu Bivalent Vaccine
Dateline City:
MADISON, N.J. First Vaccine to Offer Protection Against Both Strains of Canine InfluenzaMADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United
States and Canada, today announced that the U.S. Department of
Agriculture has approved a license for Nobivac® Canine Flu
Bivalent vaccine – the first vaccine to aid in the control of disease
associated with both canine influenza virus (CIV) H3N2 and canine
influenza virus H3N8.Language:
EnglishContact: MerckMedia:Kelly Goss, 913-558-6452kelly.goss@merck.comorPamela Eisele, 267-305-3...
Source: Merck.com - Corporate News - October 7, 2016 Category: Pharmaceuticals Tags: Corporate News Animal Health Latest News #Merck #MRK $MRK Merck Animal Health Nobivac NYSE:MRK Source Type: news
Merck to Present New Data on ZEPATIER ™ (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting® 2016
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced that new data from the company ’s chronic hepatitis C
virus (HCV) clinical development programs will be presented atThe
Liver Meeting® 2016. Fifteen scientific abstracts,
including seven oral and eight poster presentations, will highlight
findings from Merck ’s HCV clinical development programs.Language:
EnglishContact: MerckMedia:Doris Li, 908-740-1903Ian McConnell, 908-740-1921orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-...
Source: Merck.com - Corporate News - October 3, 2016 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News Source Type: news
Merck Foundation Grant Expands YMCA ’s Diabetes Prevention Program in Five States
Dateline City:
KENILWORTH, N.J. $2 Million Grant Boosts Efforts to Prevent Type 2 Diabetes in Participants with PrediabetesKENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation and YMCA of the USA (Y-USA) announced today that
the Merck Foundation has provided a grant of $2 million over three years
to support efforts to expand the YMCA ’s Diabetes Prevention Program
(YMCA’s DPP). This evidence-based, chronic disease prevention program
aims to improve the health of participants with prediabetes through
modest weight loss achieved by healthy eating and physical activity.Language:
Engli...
Source: Merck.com - Corporate News - September 29, 2016 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News Source Type: news
Two New Trials of Merck ’s KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016
Dateline City:
KENILWORTH, N.J. Results from KEYNOTE-024, which Studied KEYTRUDA Compared to Chemotherapy in Patients with High Levels of PD-L1 Expression, and KEYNOTE-021G, which Studied KEYTRUDA in Combination with Chemotherapy Compared to Chemotherapy Alone in Patients Regardless of PD-L1 Expression, to be Presented Comprehensive Data from Merck ’s Industry-Leading Immuno-Oncology Clinical Development Program to be Presented, with New Data in 12 CancersKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that extensive data on KEYTRU...
Source: Merck.com - Corporate News - September 28, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news
Merck to Hold Third-Quarter 2016 Sales and Earnings Conference Call on October 25
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
will hold its third-quarter 2016 sales and earnings conference call with
institutional investors and analysts at 8:00 a.m. EDT on Tuesday, Oct.
25. During the call, company executives will provide an overview of
Merck ’s performance for the quarter.Language:
EnglishContact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more (Source: Merck.com - Corporate News)
Source: Merck.com - Corporate News - September 23, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK earnings MSD NYSE:MRK Source Type: news
